CSBR - Champions Oncology, Inc.
| Previous Close | 12.85 |
| Open | 12.94 |
| Bid | 12.77 x 1100 |
| Ask | 13.54 x 800 |
| Day's Range | 12.70 - 13.45 |
| 52 Week Range | 3.05 - 17.90 |
| Volume | 205,072 |
| Avg. Volume | 253,315 |
| Market Cap | 142.569M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Dec 5, 2018 - Dec 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.33 |
- Zacks•9 days ago
Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?
Is (CSBR) Outperforming Other Medical Stocks This Year?
- Zacks•17 days ago
Bull Of The Day: Champions Oncology (CSBR)
Bull Of The Day: Champions Oncology (CSBR)
- Zacks•20 days ago
Best ETFs & Stocks From the Top Sector of Q3
Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.
- Zacks•last month
Looking for a Top Momentum Pick? Why Champions Oncology (CSBR) is a Great Choice
Does Champions Oncology (CSBR) have what it takes to be a top stock pick for momentum investors? Let's find out.
- PR Newswire•last month
Champions Oncology Reports Record Quarterly Revenue of $6.2 Million
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, N.J. , Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range ...
- PR Newswire•last month
Champions Oncology to Participate at the Janney Montgomery Scott Healthcare Conference 2018 in New York
HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management will participate at the Janney Montgomery Scott Healthcare Conference 2018 on Monday, September 17th in New York. To schedule a meeting, please contact your conference representative or James Carbonara at Hayden IR. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.
- Zacks•last month
Champions Oncology (CSBR) Q1 Earnings Preview: How Are Events Shaping Up?
Champions Oncology (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•2 months ago
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 13, 2018
HACKENSACK, N.J., Aug. 28, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2018, on Thursday, September 13, 2018, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 37415, or by accessing the Investor tab of the company's website within 72 hours.
- PR Newswire•2 months ago
Champions Oncology Granted Full Accreditation by the AAALAC
The new facility was designed and constructed in the first half of 2017 with operations initiated in July 2017. The purpose-built facility has state-of-the-art equipment, technology, and infrastructure, including individually ventilated caging, and automated water systems. Dr. Ronnie Morris, CEO of Champions Oncology commented: "The rapidity with which our Program attained Full Accreditation by AAALAC highlights our dedication to animal welfare and providing the highest quality research data to our collaborators. AAALAC International is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Nearly 1,000 companies, universities, hospitals, government agencies and other research institutions in 46 countries have earned AAALAC accreditation, demonstrating their commitment to responsible animal care and use.
- PR Newswire•3 months ago
Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018
Expects Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, N.J. , July 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions ...
- PR Newswire•3 months ago
Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 26, 2018
HACKENSACK, N.J., July 12, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2018, on Thursday, July 26, 2018, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 34360, or by accessing the Investor tab of the company's website within 72 hours.
- PR Newswire•4 months ago
Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies
HACKENSACK, N.J., June 18, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation, Inc. (formerly National Surgical Adjuvant Breast and Bowel Project) and Puma Biotechnology, Inc. (PBYI) to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials. The first trial, NSABP FB10 is a phase II study evaluating the combination of trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer (NCT02236000) and is currently enrolling patients.
- PR Newswire•6 months ago
Champions Oncology to Present at the 3rd annual Disruptive Growth & Healthcare Conference on May 9th
HACKENSACK, N.J., May 3, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Wednesday, May 9th at 8:40am. The conference is being hosted by RHK Capital and ReedSmith LLP, at Reed Smith's offices located at 599 Lexington Avenue. The 2018 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.
- PR Newswire•6 months ago
Champions Oncology Adds Amy Wesa, Ph.D, as Director of Immuno-Oncology Research
HACKENSACK, N.J., May 1, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Amy Wesa, Ph.D, has joined the company as Director of Immuno-Oncology Research. Ronnie Morris, CEO of Champions Oncology commented, "The appointment of Dr. Wesa demonstrates our long-term commitment to help pharmaceutical companies make better decisions as they develop immunotherapeutics. Immuno-oncology represents a fast growing part of the oncology drug pipeline.
- PR Newswire•7 months ago
Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House
HACKENSACK, N.J., April 4, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year's MicroCap Conference on Tuesday, April 10, 2018 at 9:30am. The MicroCap Conference will take place in New York City at the Essex House on April 9th and 10th.
- ACCESSWIRE•7 months ago
Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes
Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: ...
- PR Newswire•7 months ago
Champions Oncology Reports Quarterly Revenue of $5.1 Million
Company Generates Positive Cash Flow from Operations; Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2018 HACKENSACK, N.J. , March 15, 2018 /PRNewswire/ -- Champions Oncology, ...
- ACCESSWIRE•7 months ago
Champions Oncology, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Champions Oncology, Inc. (NASDAQ: CSBR ) will be discussing their earnings results in their Q3 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern ...
- Simply Wall St.•7 months ago
Does Champions Oncology Inc’s (NASDAQ:CSBR) Past Performance Indicate A Stronger Future?
Assessing Champions Oncology Inc’s (NASDAQ:CSBR) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check toRead More...
- PR Newswire•7 months ago
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 15, 2018
HACKENSACK, N.J., March 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2018, on Thursday, March 15, 2018, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 26851, or by accessing the Investor tab of the company's website within 72 hours.
- Simply Wall St.•8 months ago
How Financially Strong Is Champions Oncology Inc (NASDAQ:CSBR)?
Investors are always looking for growth in small-cap stocks like Champions Oncology Inc (NASDAQ:CSBR), with a market cap of US$39.12M. However, an important fact which most ignore is: how financiallyRead More...
- PR Newswire•8 months ago
Champions Oncology to Participate at the 30th Annual ROTH Conference
HACKENSACK, N.J., Feb. 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will participate at the 30th Annual Roth Conference and will conduct one-on-one meetings. The conference will be held March 11-13, 2018 at The Ritz Carlton, Laguna Niguel in Orange County, CA and is by invitation only. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.
- PR Newswire•8 months ago
Motivated Patients with ROS1 Cancer Initiate Global Research Study
SAN CARLOS, Calif. and HACKENSACK, N.J., Feb. 21, 2018 /PRNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX) models for ROS1-fusion driven cancers to understand what drives tumor development, therapeutic response and acquired resistance to enable the development of new and more effective therapies against this under-studied molecular subset of cancer.
